Summary
- AD an inflammatory disease involving immune dysregulation and epidermal barrier breakdown
- Disease negatively affects QOL and leads to multiple comorbidities
- Diagnosis of exclusion based on clinical presentation
- Patient severity assessments are helpful
- Multiple treatments available depending on disease severity
- Systemic immunosuppression not suitable for long-term maintenance
- Dupilimab the only biologic thus far available
- Trials show long-term efficacy
- Carful documentation needed for coverage
- Several biologic and small-molecule agents now in development